Search

Your search keyword '"Amidou Diarra"' showing total 170 results

Search Constraints

Start Over You searched for: Author "Amidou Diarra" Remove constraint Author: "Amidou Diarra"
170 results on '"Amidou Diarra"'

Search Results

1. Force of Infection (FOI) and Multiplicity of Infection (MOI) in Plasmodium falciparum Infected Children Aged 1.5–12 Years Living in the Malaria Endemic Area of Banfora, Burkina Faso

2. Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial

3. Hospital-based surveillance of severe paediatric malaria in two malaria transmission ecological zones of Burkina Faso

4. Impact of Plasmodium falciparum infection on DNA methylation of circulating immune cells

5. Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5–10-Year-Old Burkinabe Children Naturally Exposed to Malaria

6. Contribution of the Rapid LAMP-Based Diagnostic Test (RLDT) to the Evaluation of Enterotoxigenic Escherichia coli (ETEC) and Shigella in Childhood Diarrhea in the Peri-Urban Area of Ouagadougou, Burkina Faso

7. Malariometric Indices in the Context of Seasonal Malaria Chemoprevention in Children Aged 1.5 to 12 Years during the Period of High Malaria Transmission in the Suburban Area of Banfora, Burkina Faso

8. Risk of Plasmodium falciparum infection in south-west Burkina Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention

9. Assessment of the transmission blocking activity of antimalarial compounds by membrane feeding assays using natural Plasmodium falciparum gametocyte isolates from West-Africa.

10. African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination

11. Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso

12. Risk factors for Plasmodium falciparum infection in pregnant women in Burkina Faso: a community-based cross-sectional survey

13. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial

14. Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children

15. Prevalence and predictors of vitamin D deficiency in young African children

16. Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso

17. Integrative genomic analysis reveals mechanisms of immune evasion in P. falciparum malaria

18. A cohort study to identify risk factors for Plasmodium falciparum infection in Burkinabe children: implications for other high burden high impact countries

19. Estimating the burden of iron deficiency among African children

20. A review of 65 years of human adenovirus seroprevalence

21. Biology of Plasmodium falciparum gametocyte sex ratio and implications in malaria parasite transmission

22. Vitamin D Deficiency and Its Association with Iron Deficiency in African Children

23. Antibody responses to P. falciparum blood stage antigens and incidence of clinical malaria in children living in endemic area in Burkina Faso

24. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.

25. Variation in haematological parameters in children less than five years of age with asymptomatic Plasmodium infection: implication for malaria field studies

26. Clinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso

27. Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).

28. Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods.

29. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.

30. Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso.

31. Transplacental Transmission of Plasmodium falciparum in a Highly Malaria Endemic Area of Burkina Faso

32. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.

33. Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial.

34. Correction: Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children.

35. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

36. A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria

37. Risk factors for Plasmodium falciparum infection in pregnant women in Burkina Faso: a community-based cross-sectional survey

38. High-resolution African HLA resource uncoversHLA-DRB1expression effects underlying vaccine response

39. Prevalence of Neutralizing Antibodies against Adenoviruses types -C5, -D26 and -B35 used in vaccination platforms, in Healthy and HIV-Infected Adults and Children from Burkina Faso and Chad

40. Malaria is a cause of iron deficiency in African children

41. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial

42. Hospital Based Surveillance of Severe Paediatric Malaria in Two Malaria Transmission Ecological Zones of Burkina Faso

43. Distribution of msp1, msp2 and eba175 Allelic Family According to Hemoglobin Genotype and G6PD Type from Children with Uncomplicated Malaria in Banfora Heath District (Burkina Faso)

44. Prevalence of Plasmodium falciparum Chloroquine Resistance Transporter (Pfcrt76T) Mutation Associated with Antimalarial Drug Resistance in Two Different Epidemiological Setting (Banfora and Saponé) in Burkina Faso Few Years after the Implementation of Artemisnine Based Combination Therapy (ACTs)

45. Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso

46. Vitamin D deficiency and its association with iron deficiency in African children

47. Abnormalities of Hemoglobin and Glucose-6-Phosphate-Dehydrogenase Deficiency in Children with Uncomplicated Malaria and Living in Banfora and Saponé, Two Different Malaria Setting of Burkina Faso

48. Seasonal Depiction of Malariometric Indices in Children under Five Years in a Sudanese Semi-urban Area of Burkina Faso

49. The Impact of Human Genetic Factors (G6pd and Type of Hemoglobin) on the Course of Uncomplicated Malaria Infection in Children Aged from 2 to 10 Years Living in the Banfora Health District in Burkina Faso

50. Prevalence and predictors of vitamin D deficiency in young African children

Catalog

Books, media, physical & digital resources